🔗 Share this article

While the US proceeds with historic changes to its vaccination schedules, one figure appears unexpectedly: Høeg, an American of Danish descent physician and epidemiologist who first made her name by casting doubt on coronavirus vaccinations during the global health crisis and has focused upon possible deaths after Covid vaccination in her short position at the FDA.

Scheduled Changes to Pediatric Vaccine Schedule

Public health authorities had intended to reveal sweeping changes to the pediatric vaccination calendar earlier this month, synchronizing the US with Denmark’s vaccine program, according to reports – a major change that would place the US out of step with a large portion of the global community with no evidence for improved outcomes. This reveal has been postponed until the coming year.

Rather than the director of the vaccine center, Dr. Høeg is scheduled to present at the gathering. She was newly appointed temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to head the center this calendar year.

A Shift at the Agency

This interim role may indicate a tighter collaboration between the drug and vaccine branches as Høeg and Dr. Prasad consolidate power at the regulatory agency – and it suggests a greater focus upon dismantling previously authorized immunizations at the FDA.

Høeg has repeatedly called for ending certain pediatric vaccine recommendations in the US in order to be more like Denmark, a society with nationalized medicine and a citizenry roughly the population of the state of Wisconsin.

In her initial statements, she has kept her attention on vaccines – typically the domain of Prasad, chief of the FDA’s CBER – instead of pharmaceutical oversight.

Concerns Over Background

Høeg has little discernible experience in pharmaceutical research, regulation or management, which has been typical for past directors of the biologics center. She has worked at the FDA as a key advisor to the agency head and the vaccine center since spring.

“It seems she lacks to have the necessary background” for leading the CDER, stated Dr. Jonathan Howard. “She lacks experience running a scientific study. She has no expertise in managing a sizeable institution. She is not an expert in industry regulation.”

Former commissioners of the center would “understand regulatory frameworks and the research of pharmaceutical innovation”, noted Dr. Janet Woodcock. “Frankly, she doesn’t have the type of experience that previous people who led the center have had.”

The drug center has an immense portfolio at the agency, the former commissioner stated.

“The public just zeroes in on the new drug program, but the generic drug division authorizes a multitude of off-brand pharmaceuticals. There is also a biosimilars program, non-prescription drug unit and so forth, and each of these must be looked after,” she noted. “The responsibility you overlook, that’s the thing that I always told people is going to come back to haunt you.”

Additionally, a major leadership element to the role, which oversees in excess of 5,000 employees. “It is a enormous leadership role, if you do it right,” the former official concluded.

Official Statement and Disputed Policies

When asked about inquiries about Dr. Høeg's fitness for the role and whether this appointment signifies greater collaboration among FDA leaders on vaccines, a press secretary said that the “questions rely on flawed presumptions”.

“Her resume matches the responsibilities of her job,” the representative said, citing the months Høeg spent advising the agency head on “drug safety and approval science, including computerized risk analysis and vaccine surveillance”.

As acting director, Høeg assumes responsibility for the commissioner’s new priority voucher program, a controversial rapid therapy clearance system that apparently worried her preceding directors. “By what process are these therapies being chosen for this voucher program? Who is making the decisions?” Dr. Howard said. “There is a lot of secrecy happening at the regulatory body right now.”

Broadly speaking, he said, “the Food and Drug Administration seems to be moving towards less stringent regulations of all drugs, aside from immunizations.”

Public Past Work on Immunizations

Regarding immunizations, Høeg has a more established, if troubling, history, some experts said. She released a research paper using unverified crowd-sourced reports to determine the frequency of heart inflammation after COVID-19 immunization. She counseled the state of Florida top health official Dr. Joseph Ladapo, who allegedly have modified findings to suggest COVID-19 vaccinations are riskier than they are.

Included in her “wish list” for the new federal leadership included altering rules for new vaccines and ending “optional” vaccines, she said post-election on a podcast. At the FDA, Høeg has allegedly proposed preventing teenage boys from obtaining Covid vaccinations.

“She’s an all-around dogmatist who begins with her conclusions and works backwards to retrofit the data in a highly misleading, fraudulent manner,” Dr. Howard argued.

Consolidating Power and a “Push for Payback”

Høeg became part of other dissenters, {like|